Evotec has a strong expertise in hit identification and can support its clients screening campaigns through multiple platforms including virtual, biochemical, biophysical, cell and phenotypic based screening with high-throughput capabilities.
For screening campaigns, Evotec has the flexibility to screen large client compound collections, its own 450,000 Evotec and 400,000 Aptuit compounds collection and additional 700,000 molecules from the Sanofi library.
Evotec state-of-the-art platforms offer a large variety of detection technologies, assay development and miniaturisation capabilities and the use of multiple read-out parameters to enable the reduction of false positives and negatives. In addition, Evotec offers to review hit compounds from a biological and medicinal chemistry point of views to ensure that compounds further progressed have the required drug like profiles.
Through an understanding of each client’s project requirements and goals, our experienced screening team will design the most adequate hit identification campaign ensuring the highest chance of success.